Interaction between oral estrogen plus progestogen therapy and ABO blood groups on coagulation activation in postmenopausal women

Menopause

Volumn 19, Issue 3, 2012, Pages 339-345

  Guimarães, Daniela Amorim Melgaço ^a,b   Dos Santos, Mariana Silva ^a   Gomes, Karina Braga ^a   Van Der Bom, Johanna G ^c   Rios, Danyelle Romana ^a,d   Cardoso, Jarbas ^a   Franco, Romerson Martins ^e   Teixeira, George Da Silva ^c   Dusse, Luci Maria Sant'Ana ^a   Carvalho, Maria Das Graças ^a   Fernandes, Ana Paula ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Academic of Pharmacy of Federal University São João Del Rei   (Brazil)

^e Maternity Otaviano Neves   (Brazil)

Author keywords

ABO blood groups; Hypercoagulability markers; Postmenopausal hormone therapy; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 8; D DIMER; ESTRADIOL; NORETHISTERONE ACETATE; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD GROUP ABO SYSTEM; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POSTMENOPAUSE; PROSPECTIVE STUDY;

ABO BLOOD-GROUP SYSTEM; BLOOD COAGULATION; ESTROGENS; FACTOR VIII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROGESTINS; PROSPECTIVE STUDIES; THROMBOPHILIA; VON WILLEBRAND FACTOR;

EID: 84857609971     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31822b721f     Document Type: Article

References (52)

1. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209-1218. (Pubitemid 35449187)
2. Wren BG. The benefits of oestrogen following menopause: why hormone replacement therapy should be offered to postmenopausal women. Med J Aust 2009;190:321-325.
3. Scarabin PY, Oger E, Plu-Bureau G for the Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432. (Pubitemid 36999704)
4. Douketis JD, Julian JA, Kearon C, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 2005;3:943-948. (Pubitemid 41632824)
5. Cushman M, Kuller LH, Prentice R, et al, for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-1580. (Pubitemid 39314963)
6. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005;94:17-25. (Pubitemid 40974700)
7. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845. (Pubitemid 46294724)
8. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-1231. (Pubitemid 351809317)
9. Canonico M, Scarabin PY. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Climacteric 2009;1:76-80.
10. Sandset PM, HLibraaten E, Eilertsen AL, Dahm A. Mechanisms of thrombosis related to hormone therapy. Thromb Res 2009;2:S70-S73.
11. Olié V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010;17:457-463.
12. Olié V, Canonico M, Scarabin PY. Postmenopausal hormone therapy and venous thromboembolism. Thromb Res 2011;3:S26-S29.
13. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism:results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-345.
14. Ohira T, Folsom AR, Cushman M, et al. Reproductive history, hormone replacement, and incidence of venous thromboembolism: the longitudinal investigation of thromboembolism etiology. Br J Haematol 2010;149: 606-612.
15. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979-986.
16. Teede HJ, McGrath BP, Smolich JJ, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000;20:1404-1409. (Pubitemid 30262946)
17. Douketis JD, Gordon M, Johnston M, Julian JA, Adachi JR, Ginsberg JS. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. Thromb Res 2000;99:25-34. (Pubitemid 30440738)
18. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625. (Pubitemid 32293696)
19. Lowe GDO, Upton MN, Rumley A, McConnachie A, O'Reilly DSJ, Watt GCM. Different effects of oral transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive proteina: a cross-sectional population survey. Thromb Haemost 2001;86: 550-556. (Pubitemid 32743265)
20. Salobir BG, Keber I, Vrabic L. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil Steril 2002;79:1178-1183. (Pubitemid 35463111)
21. Guimarães DA, Carvalho MG, Souza MO, et al. Assessment of hypercoagulability markers and lipid levels in postmenopausal women under either oral or transdermal hormone replacement therapy. J Thromb Thromb 2009;27:135-140.
22. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23: 1116-1121. (Pubitemid 36713570)
23. Fait T, Vrablik M, Zizka Z, Kostirova M. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study. Gynecol Obstet Invest 2008;65:47-51.
24. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006;13:643-650. (Pubitemid 44079534)
25. Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, et al. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women. Climacteric 2007;10:400-407. (Pubitemid 47402945)
26. Sgarabotto M, Baldini M, Dei Cas A, et al. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study. Thromb Res 2007;119:85-91. (Pubitemid 44716210)
27. Bonduki CE, Louren0o DM, Motta EL, Soares JM Jr, Haidar MA, Baracat EC. Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women. Clinics 2007;62:553-560.
28. Ruszkowska B, Gadomska G, Bielis L, et al. Risk of venous thromboembolic disease in postmenopausal women taking oral or transdermal hormone replacement therapy. J Zhejiang Univ Sci B 2011;12:12-17.
29. Borgfeldt C, Li C, Samsioe G. Low-dose oral combination of 17Aestradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor (Pubitemid 38367166)
30. Cosman F, Baz-Hecht M, Cushman M, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 2005;116:1-13.
31. Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl GLM. Relation between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2004;128:100-107.
32. Morelli VM, De Visser MCH, Vos HL, Bertina RM, Rosendaal, FR. ABO blood group genotypes and risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost 2005;3:183-185. (Pubitemid 41647137)
33. Paiva SG, De Paula Sabino A, Carvalho MG, et al. Polymorphisms in exons 6 and 7 of the ABO locus and their association with venous thrombosis in young Brazilian patients. Blood Coagul Fibrinolysis 2009; 20:122-128.
34. Kamphuisen PW, Eikenboom JCJ, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21:731-738. (Pubitemid 32448761)
35. Jenkins PV, O'Donnel JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006;46:1836-1844. (Pubitemid 44435738)
36. Morelli VM, De Visser MCH, Van Tilburg NH, Vos HL, Eikenboom JCJ, Rosendaal RR. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 2007;97:534-541. (Pubitemid 46592929)
37. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003;1:33-42.
38. Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas 2006;55:278-287. (Pubitemid 44397354)
39. Canonico M, Olié V, Carcaillon L, Tubert-Bitter P, Scarabin PY. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: the ESTHER study. Thromb Haemost 2008;99:246-248.
40. Michiels JJ, Gadisseur A, Van der Planken M, et al. Screening for deep vein thrombosis and pulmonary embolism in outpatients with suspected DVT or PE by the sequential use of clinical score: a sensitive quantitative D-dimer test and noninvasive diagnostic tools. Semin Vasc Med 2005;5:351-364. (Pubitemid 41513118)
41. Lim HS, Lip GY, Blann AD. Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension. J Clin Endocrinol Metab 2004;89:5377-5381. (Pubitemid 39518411)
42. Mulder R, van Schouwenburg IM, Mahmoodi BK, et al. Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: results from a retrospective family cohort study. Thromb Res 2010;126: 249-254.
43. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
44. Souto JC, Almasy L, Muñiz-Diaz E, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand Factor, Factor VIII, and activate partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000;20:2024-2028. (Pubitemid 30644654)
45. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-462. (Pubitemid 30646484)
46. Legnani C, Cini M, Cosmi B, Poggi M, Boggian O, Palareti G. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. Haematologica 2004;89:1347-1351. (Pubitemid 39540572)
47. Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk. Br J Haematol 2010;149:118-123.
48. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001;115:415-420. (Pubitemid 34203511)
49. Eilertsen AL, Liestol S, Mowinckel MC, Hemker HC, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost 2007;97:938-943. (Pubitemid 46939206)
50. Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. Thromb Res 2007;120:371-379. (Pubitemid 46879904)
51. van Vliet HA, Bertina RM, Dahm AE, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2008;6:346-351.
52. Soares AL, Rosário PW, Borges MA, Sousa MO, Fernandes AP, Carvalho MG. PAI-1 and D-dimer in type 2 diabetic women with asymptomatic macrovascular disease assessed by carotid Doppler. Clin Appl Thromb Hemost 2010;16:204-208.